<?xml version="1.0" encoding="UTF-8"?>
<ref id="b76-ijmm-46-02-0489">
 <label>76</label>
 <element-citation publication-type="web">
  <person-group person-group-type="author">
   <name>
    <surname>Channappanavar</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Xia</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Du</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Meyerholz</surname>
    <given-names>DK</given-names>
   </name>
   <name>
    <surname>Perlman</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Jiang</surname>
    <given-names>S</given-names>
   </name>
  </person-group>
  <article-title>Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. - Abstract - Europe PMC</article-title>
  <comment>
   <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/article/med/26164863" xmlns:xlink="http://www.w3.org/1999/xlink">https://europepmc.org/article/med/26164863</ext-link>
  </comment>
 </element-citation>
</ref>
